The biochemical differences between penicillamine and thiomalate are mainly due to the lack of an amino group in the latter molecule. Interaction of the two drugs with aldehyde-groups, e.g. in crosslinking of collagen, will be different: both penicillamine and thiomalate will form hemithioacetals with aldehydes, but only penicillamine will cyclize to form the thiazolidine ring. Only penicillamine and its disulphide will become reversibly bound to DNA (Fig 5) . Thiomalate which does not contain the positively charged amino group cannot interact with the negatively charged phosphate groups of the DNA molecules. Finally, it is highly probable that the transport mechanism of the aminoacid penicillamine will be different from that of thiomalate, a dicarboxylic acid. Also the metabolic degradation of the two compounds will be different.
Conclusions
From the above results and discussion it is evident that thiomalate and protein-bound (mainly albumin-bound) gold are likely to exist in vivo after gold thiomalate injection. Since there are many biochemical similarities between thiomalate and penicillamine, one would like to establish with certainty whether or not thiomalate has an effect on rheumatoid arthritis in man. Animal models must be used with caution, as recently emphasized by Willoughby & Dieppe (1976) . It seems to us that the time has now come to carry out controlled clinical trials so that the question can be settled once and for all. Irrespective of the outcome of such a trial, the results would be almost equally interesting. Should both D-and L-thiomalate (tested separately) be without effect, one should consider eliminating this thiol from the drug Myocrisin, and perhaps use albumin-bound gold instead. Should D-or L-thiomalate have effects in man similar to that ofpenicillamine, one should examine which of the two thiols, penicillamine or thiomalate, is best tolerated. Perhaps one should also start a search for thiols with better effects and/or fewer side-effects. 
